Expanded Drug Price Negotiations to Cover Additional High-Cost Medications

Federal health officials have announced the next group of high-cost prescription drugs that will be subject to negotiated pricing under Medicare, expanding a program that has already delivered significant savings on treatments for diabetes and heart disease.

The newly selected medications include therapies for cancer, autoimmune conditions, and rare diseases, some of which currently carry annual price tags exceeding $100,000 per patient. Negotiated prices for the new group are scheduled to take effect in 2028.

Patient advocacy groups welcomed the expansion, noting that out-of-pocket costs remain a leading cause of financial strain for families managing chronic and serious illnesses. The program is projected to save the federal government and patients tens of billions of dollars over the coming decade.

Pharmaceutical manufacturers have raised concerns about the impact on research investment, while health economists debate the balance between affordability and innovation. For now, the expansion signals a continued shift in how the nation addresses the cost of life-saving medications.